Traders Buy Shares of Agilent Technologies (A) on Weakness

Investors bought shares of Agilent Technologies Inc (NYSE:A) on weakness during trading hours on Monday. $61.41 million flowed into the stock on the tick-up and $24.91 million flowed out of the stock on the tick-down, for a money net flow of $36.50 million into the stock. Of all companies tracked, Agilent Technologies had the 16th highest net in-flow for the day. Agilent Technologies traded down ($0.05) for the day and closed at $71.97

A number of equities research analysts recently weighed in on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Agilent Technologies from $75.00 to $80.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Cowen reissued a “hold” rating and set a $70.00 target price on shares of Agilent Technologies in a research report on Wednesday, November 22nd. Robert W. Baird reissued a “buy” rating and set a $72.00 target price on shares of Agilent Technologies in a research report on Friday, November 24th. Evercore ISI began coverage on shares of Agilent Technologies in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $75.00 target price on the stock. Finally, Zacks Investment Research raised shares of Agilent Technologies from a “hold” rating to a “buy” rating and set a $76.00 target price on the stock in a research report on Tuesday, October 31st. Five research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $70.98.

The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.78 and a current ratio of 3.23. The company has a market capitalization of $22,960.00, a PE ratio of 31.73, a P/E/G ratio of 2.41 and a beta of 1.28.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Wednesday, February 14th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.08. Agilent Technologies had a net margin of 4.25% and a return on equity of 17.70%. The firm had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.16 billion. During the same quarter in the previous year, the firm earned $0.53 EPS. analysts expect that Agilent Technologies Inc will post 2.67 EPS for the current year.

In other news, insider Patrick Kaltenbach sold 5,000 shares of Agilent Technologies stock in a transaction that occurred on Tuesday, November 28th. The shares were sold at an average price of $69.56, for a total value of $347,800.00. Following the transaction, the insider now owns 75,504 shares of the company’s stock, valued at approximately $5,252,058.24. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Michael R. Mcmullen sold 43,703 shares of Agilent Technologies stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $70.00, for a total transaction of $3,059,210.00. Following the completion of the transaction, the chief executive officer now directly owns 302,837 shares in the company, valued at approximately $21,198,590. The disclosure for this sale can be found here. In the last ninety days, insiders sold 154,707 shares of company stock worth $10,944,828.

Institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its stake in Agilent Technologies by 8.1% in the 4th quarter. BlackRock Inc. now owns 25,665,358 shares of the medical research company’s stock worth $1,718,808,000 after purchasing an additional 1,912,186 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Agilent Technologies by 325.0% in the 4th quarter. Renaissance Technologies LLC now owns 2,370,200 shares of the medical research company’s stock worth $158,732,000 after purchasing an additional 1,812,500 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in Agilent Technologies by 145.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,726,929 shares of the medical research company’s stock worth $115,652,000 after purchasing an additional 1,023,099 shares in the last quarter. TimesSquare Capital Management LLC acquired a new stake in Agilent Technologies in the 3rd quarter worth approximately $58,550,000. Finally, Bank of Montreal Can boosted its stake in Agilent Technologies by 187.3% in the 4th quarter. Bank of Montreal Can now owns 742,001 shares of the medical research company’s stock worth $49,693,000 after purchasing an additional 483,721 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/21/traders-buy-shares-of-agilent-technologies-a-on-weakness.html.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply